REGISTER
First in China: AstraZeneca’s Eculizumab Wins Another Approval
AstraZeneca’s eculizumab has been approved in China for children aged 6 years and older with anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis, becoming the first and only targeted therapy approved in China for pediatric patients with this disease.

On January 26, AstraZeneca announced that the NMPA had approved Soliris (eculizumab injection) for an expanded indication: treatment of pediatric patients aged 6 years and older with anti-acetylcholine receptor (AChR) antibody-positive refractory generalized myasthenia gravis (gMG). According to the press release, it is currently the first and only targeted therapy approved in China for pediatric patients with this disease.

gMG is a rare, disabling, chronic autoimmune neuromuscular disease that can lead to loss of muscle function and severe weakness.

Eculizumab is the world’s first C5 complement inhibitor. It works by selectively inhibiting activation of terminal complement C5. The complement system is an important part of the human immune system, but when activated in an uncontrolled way, it can cause the body to attack its own healthy cells.

In 2023, eculizumab was approved in China for adult patients with anti-AChR antibody-positive refractory generalized myasthenia gravis.

This approval was based on positive results from the Phase III clinical trial ECU-MG-303 in pediatric patients with refractory gMG. In the study, eculizumab produced a highly statistically significant and clinically meaningful improvement from baseline in total Quantitative Myasthenia Gravis (QMG) score at Week 26 (-5.8 [95% CI: -8.4, -3.13]; p=0.0004).

The efficacy and safety of eculizumab in children aged 6 years and older with refractory gMG were consistent with its performance in adult refractory gMG clinical trials.

At present, eculizumab has been approved globally for multiple indications, including treatment of certain pediatric and adult patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and adult patients with neuromyelitis optica spectrum disorder (NMOSD) in the United States, the European Union, Japan, China, and other countries.

*Eculizumab is not indicated for patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (STEC-HUS).

0
0
Loading